Artera Stock

artera.aiHealthcareFounded: 2021Funding to Date: $89.5MM

Artera, founded in 2021, is a precision medicine company and the developer of multimodal artificial intelligence-based predictive and prognostic tests with the goal of personalizing therapy for cancer patients. Artera’s flagship test is the ArteraAI Prostate Test, seeking to predict therapy benefit in localized prostate cancer. Artera is headquartered in Los Altos, California.

Register for Details

For more details on financing and valuation for Artera, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Artera.

Register Today

Artera investors also invested in these private companies

Team

Management Team

Andre Esteva Ph.D
Co-Founder, Chief Executive Officer & Board Member

Other companies like Artera in the Healthcare sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$809.52MM
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$400.53MM
Sector
Last Round Est. Valuation
$1.53B
Sector
Last Round Est. Valuation
$409.37MM

News

Artera, a medical company developing AI tests to personalize therapy for cancer patients, raised $90 million, the company tells Axios exclusively.
Artera, which uses artificial intelligence for cancer testing and personalized care, raised a $90 million round to support the distribution of its flagship test in prostate cancer.
An artificial intelligence-derived biomarker enabled improved risk stratification for men with high-risk prostate cancer, according to study results presented at ASCO Genitourinary Cancers Symposium.
Updated on: Jun 2, 2023